PMID- 18854284
OWN - NLM
STAT- MEDLINE
DCOM- 20081231
LR  - 20220311
IS  - 1557-9190 (Print)
IS  - 1557-9190 (Linking)
VI  - 8
IP  - 5
DP  - 2008 Oct
TI  - Serum C-reactive protein at diagnosis and response to therapy is the most 
      powerful factor predicting outcome of multiple myeloma treated with thalidomide/ 
      anthracycline-based therapy.
PG  - 294-9
LID - 10.3816/CLM.2008.n.041 [doi]
AB  - BACKGROUND: Few studies have focused on factors affecting outcome in patients 
      with multiple myeloma (MM) treated with thalidomide-based therapy. We 
      investigated factors affecting response, progression-free survival (PFS), and 
      overall survival (OS) in patients with MM treated with the thalidomide, 
      dexamethasone, and pegylated liposomal doxorubicin (ThaDD) regimen with the aim 
      to select patients benefiting more from this therapy. PATIENTS AND METHODS: 
      Sixty-six patients with MM were treated first line with the ThaDD regimen. We 
      analyzed demographics and disease-related characteristics to search for factors 
      affecting response (> or = very good partial remission [VGPR] vs. < VGPR], PFS, 
      and OS. RESULTS: Overall, 45 patients (68%) showed response > or = VGPR; median 
      TTP and OS were 23.5 months and 35.5 months, respectively. Multivariate analysis 
      selected only serum C-reactive protein (sCRP) as a predictive factor for response 
      (P < .0001). By multivariate analysis, normal sCRP level (P = .001) and response 
      to treatment > or = VGPR (P = .007) were found to be associated with longer PFS. 
      The factors that remained significantly associated with a longer OS when assessed 
      by multivariate analysis were normal sCRP level (P = .005) and response to 
      therapy > or = VGPR (P = .019). CONCLUSION: Serum C-reactive protein before 
      therapy and response after therapy are the only factors useful in identifying 
      patients benefiting from anthracycline/thalidomide-based therapy.
FAU - Offidani, Massimo
AU  - Offidani M
AD  - Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti Ancona, 
      Italy. m.offidani@ospedaliriuniti.marche.it
FAU - Corvatta, Laura
AU  - Corvatta L
FAU - Polloni, Claudia
AU  - Polloni C
FAU - Piersantelli, Maria-Novella
AU  - Piersantelli MN
FAU - Galieni, Piero
AU  - Galieni P
FAU - Visani, Giuseppe
AU  - Visani G
FAU - Alesiani, Francesco
AU  - Alesiani F
FAU - Catarini, Massimo
AU  - Catarini M
FAU - Brunori, Marino
AU  - Brunori M
FAU - Burattini, Maurizio
AU  - Burattini M
FAU - Centurioni, Riccardo
AU  - Centurioni R
FAU - Ferranti, Mario
AU  - Ferranti M
FAU - Giuliodori, Luciano
AU  - Giuliodori L
FAU - Candela, Marco
AU  - Candela M
FAU - Mele, Anna
AU  - Mele A
FAU - Marconi, Monica
AU  - Marconi M
FAU - Leoni, Pietro
AU  - Leoni P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Lymphoma Myeloma
JT  - Clinical lymphoma & myeloma
JID - 101256500
RN  - 0 (Anthracyclines)
RN  - 0 (Biomarkers)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Aged
MH  - Anthracyclines/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers/*analysis
MH  - C-Reactive Protein/*analysis
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*blood/mortality/pathology/*therapy
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Risk Factors
MH  - Survival Analysis
MH  - Thalidomide/administration & dosage
MH  - Treatment Outcome
EDAT- 2008/10/16 09:00
MHDA- 2009/01/01 09:00
CRDT- 2008/10/16 09:00
PHST- 2008/10/16 09:00 [pubmed]
PHST- 2009/01/01 09:00 [medline]
PHST- 2008/10/16 09:00 [entrez]
AID - S1557-9190(11)70255-4 [pii]
AID - 10.3816/CLM.2008.n.041 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma. 2008 Oct;8(5):294-9. doi: 10.3816/CLM.2008.n.041.